Amycretin (NN9487) — what it does, evidence, and safety

What it is

Amycretin is a Novo Nordisk compound studied for weight loss and blood-sugar control in early-stage research — it's designed to activate both the GLP-1 and amylin receptors in a single molecule, and has been tested in two forms: a once-weekly injection under the skin and a once-daily oral tablet. It is investigational and not approved by the FDA for any use; a Phase 3 program began recruiting in 2026.

What the research found

Amycretin has been studied as a weekly (injected) or daily (oral) treatment for obesity and type 2 diabetes. In a Phase 1b/2a trial of the injected form (published in The Lancet), once-weekly amycretin was associated with average body-weight reductions of up to about 24.3% at the highest dose over 36 weeks, versus roughly 1% on placebo. A Phase 2 trial in type 2 diabetes reported weight reductions of up to about 14.5% (injected) and 10.1% (oral) plus HbA1c reductions over 36 weeks. Gastrointestinal effects were the most common side effects across trials and were mostly mild to moderate; the early injected trial also saw a high number of withdrawals, many for reasons unrelated to side effects. The research attributes these weight and blood-sugar changes largely to reduced appetite and food intake (greater satiety via the gut-hormone pathway these agents act on), an appetite and energy-intake mechanism measured across the trials.

Status and regulatory position

Investigational (not FDA approved); Phase 3 (AMAZE) program underway — recruiting since Q1 2026. WADA: not specifically named; as an investigational compound with no approval it could fall under S0 (non-approved substances) for tested athletes — verify with your anti-doping organization. Not DEA-scheduled.

Safety

Amycretin is investigational and not FDA-approved for any indication. In its early trials the most commonly reported effects were gastrointestinal (nausea, vomiting, diarrhea), mostly mild to moderate, consistent with the GLP-1 and amylin agonist classes; the Phase 1b/2a trial also reported a high number of participant withdrawals. Long-term safety has not been established. Amycretin is not specifically named on the WADA Prohibited List, but as an investigational compound with no regulatory approval it could fall under the S0 (non-approved substances) category for tested athletes — anyone in regulated sport should verify with their anti-doping organization. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

Disclosures

⚠️ For research and educational purposes only. Amycretin is an investigational compound not approved by the FDA for any indication. Information in this entry is informational, not medical advice. Always confirm any dose figures with the in-app calculator and consult appropriate professional guidance before any decisions.

⚠️ Two different forms. Amycretin has been studied as both a once-weekly subcutaneous injection and a once-daily oral tablet. The oral form is a pill — no reconstitution applies to it. The figures below specify which form each result came from; do not mix the two.

Quick reference

Forms studied	Once-weekly subcutaneous injection; once-daily oral tablet[¹][²][³]
Mechanism	Single-molecule dual GLP-1 + amylin receptor agonist[¹]
Frequency	Subcutaneous: once weekly. Oral: once daily.[¹][²][³]
Half-life	No published pharmacokinetic half-life — unknown / no-data. A specific t½ has not been reported in the available primary literature for either form.
Route	Subcutaneous or oral (two separate formulations)
Regulatory status	Investigational; not FDA-approved. Novo Nordisk's Phase 3 AMAZE program has been recruiting since Q1 2026[⁴]

In depth

Amycretin is an investigational, single-molecule (unimolecular) dual GLP-1 and amylin receptor agonist developed by Novo Nordisk. According to PubMed, it is described as "the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule," and it has been advanced in two formulations: a once-weekly subcutaneous injection and a once-daily oral tablet.[¹][³] It is not approved by the FDA for any indication.

Phase 1b/2a (subcutaneous). According to PubMed, the Phase 1b/2a trial of subcutaneous amycretin (Dahl et al., Lancet 2025; NCT06064006, n=125: 101 amycretin / 24 placebo; single research center in San Antonio, TX) enrolled adults aged 18–55 with overweight or obesity (BMI 27.0–39.9).[¹] The trial had five parts (A–E) with once-weekly dosing escalated up to maintenance doses, or over treatment periods of 20–36 weeks. Estimated mean body-weight change from baseline was significantly greater with amycretin than placebo: −24.3% vs −1.1% (week 36), −22.0% vs +1.9% (week 36), −16.2% vs +2.3% (week 28), and −9.7% vs +2.0% (week 20).[¹] The most common adverse events were gastrointestinal, mostly mild to moderate; the authors specifically noted that a large number of participants withdrew, with many discontinuations for reasons unrelated to treatment-emergent adverse events.[¹]

Phase 2 (type 2 diabetes; subcutaneous and oral). Novo Nordisk reported (company announcement, November 25, 2025) headline results from a Phase 2 trial (NCT06542874) in 448 adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor, comparing once-weekly subcutaneous amycretin and once-daily oral amycretin to placebo over 36 weeks.[²] Per the press release, subcutaneous doses were associated with up to ~14.5% weight reduction and oral doses with up to ~10.1%; HbA1c reductions of up to ~1.8% (subcutaneous, from baseline 7.8%) and up to ~1.5% (oral, from baseline 8.0%) were reported by week 36.[²] These Phase 2 T2D figures are from a Novo Nordisk press release (November 2025), not a peer-reviewed paper, and are attributed as such; they should be reconciled against the eventual publication or congress presentation when available. As of the 2026-07-17 registry check, NCT06542874 is listed as COMPLETED (primary completion 2025-10-01), but no peer-reviewed Phase 2 T2D publication is indexed in PubMed.[⁴]

Phase 1 first-in-human (oral). According to PubMed, the first-in-human Phase 1 trial of oral amycretin (Gasiorek et al., Lancet 2025; NCT05369390, n=144) was a double-blind, randomized, placebo-controlled study run in parts A–D, with a 12-week intervention in parts C and D that included exploratory body-weight change.[³] All treatment-emergent adverse events reported in the trial were mild or moderate and predominantly gastrointestinal.[³] A 2026 review in *Metabolism* summarising the amycretin program describes body-weight reductions of up to about 13.1% with the oral form over 12 weeks and up to about 24.3% with the subcutaneous form over 36 weeks; the oral figure is attributed to that review rather than to the primary Phase 1 abstract.[⁵]

Phase 3 (AMAZE program). Per ClinicalTrials.gov, Novo Nordisk opened a Phase 3 program for amycretin in 2026 rather than merely planning one: AMAZE 1 in obesity (NCT07339423) began recruiting 2026-02-24 with a target of roughly 1,150 participants, alongside additional Phase 3 trials covering overweight/obesity with type 2 diabetes (NCT07533175), obstructive sleep apnea (NCT07571005, NCT07571109), knee osteoarthritis (NCT07481630, NCT07509307), weight maintenance (NCT07503210), a head-to-head comparison against semaglutide (NCT07400107, not yet recruiting), and a cardiovascular outcomes trial in HFpEF with obesity (NCT07567001).[⁴] These trials are ongoing and have not reported results; amycretin remains investigational and is not FDA-approved.

Reported side effects

Commonly reported

Nausea
Vomiting
Diarrhea
Other gastrointestinal effects (mostly mild to moderate)[¹][²][³]
The Phase 1b/2a trial reported a high frequency of GI events and a large number of participant withdrawals (many unrelated to adverse events)[¹]

Serious

Acute pancreatitis symptoms (class concern across incretins)
Gallbladder symptoms
Severe persistent vomiting or dehydration
Note: the items above are class-level cautions for the GLP-1 / amylin agonist classes, not amycretin-confirmed serious adverse events; no amycretin-specific serious adverse-event profile has been published.

Contraindications and warnings

Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 — class-level caution for GLP-1 receptor agonists; amycretin-specific labeling does not exist (it is investigational), so this is a class extrapolation

History of pancreatitis

Severe gastrointestinal disease

Concurrent use of other GLP-1 / amylin / incretin agonists

Pregnancy and lactation: investigational — no adequate data

Key terms

GLP-1 receptor agonist: A compound that switches on the GLP-1 receptor, the same target a natural gut hormone uses to signal fullness and help regulate blood sugar.
Amylin: A hormone released with insulin that contributes to feeling full and slows stomach emptying. Amylin-receptor activation is amycretin's second mechanism alongside GLP-1.
Subcutaneous: Given as an injection into the fatty layer just under the skin. One of amycretin's two studied forms is a once-weekly subcutaneous injection.
Oral bioavailability: The fraction of a swallowed dose that reaches the bloodstream. Amycretin has also been studied as a once-daily oral form.
Investigational: Still being studied and not yet approved by regulators for general use.

Sources

Related entries

CagriSema — same mechanism class
Dulaglutide — same mechanism class
Exenatide — same mechanism class
Liraglutide — same mechanism class
Mazdutide — same mechanism class
Orforglipron — same mechanism class